PointState Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

PointState Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-309,004	Closed	-$22.9M	–	75
2022 Q2	$22.9M	Buy	+309,004	New	+$23.2M	0.57%	25
2022 Q1	–	Sell	-65,000	Closed	-$7.28M	–	139
2021 Q4	$7.28M	Sell	65,000 -130,028	-67%	-$15.7M	0.12%	72
2021 Q3	$24.5M	Buy	+195,028	New	+$25.1M	0.41%	54
2021 Q2	–	Sell	-50,000	Closed	-$6.78M	–	168
2021 Q1	$6.78M	Buy	+50,000	New	+$7.49M	0.13%	94
2019 Q3	–	Sell	-22,800	Closed	-$2M	–	145
2019 Q2	$2M	Buy	+22,800	New	+$1.94M	0.04%	90
2018 Q1	–	Sell	-12,200	Closed	-$1.03M	–	209
2017 Q4	$1.03M	Buy	+12,200	New	+$1.02M	0.01%	145
2016 Q2	–	Sell	-19,200	Closed	-$992K	–	135
2016 Q1	$992K	Buy	+19,200	New	+$997K	0.03%	86

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

PointState Capital's XBI Position: Q3 2022 in Review

PointState Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2022, closing a stake of 309,004 shares — an estimated $22.9M sold.

PointState Capital first reported a position in XBI in Q1 2016 and held it in 7 quarters. The position peaked at $24.5M in Q3 2021. 703 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

PointState Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2022 after selling out during the quarter.
PointState Capital sold 309,004 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $22.9M.
PointState Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2016 and held it in 7 quarters.
PointState Capital's State Street SPDR S&P Biotech ETF position peaked at $24.5M in Q3 2021.
703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on PointState Capital's 13F filing for Q3 2022, filed 10 Nov 2022.